Trends in prenatal prescription opioid use among Medicaid beneficiaries in Wisconsin, 2010-2019.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
31
08
2023
accepted:
25
03
2024
revised:
20
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
To examine changes in prenatal opioid prescription exposure following new guidelines and policies. Cohort study of all (262,284) Wisconsin Medicaid-insured live births 2010-2019. Prenatal exposures were classified as analgesic, short term, and chronic (90+ days), and medications used to treat opioid use disorder (MOUD). We describe overall and stratified temporal trends and used linear probability models with interaction terms to test their significance. We found 42,437 (16.2%) infants with prenatal exposure; most (90.5%) reflected analgesic opioids. From 2010 to 2019, overall exposure declined 12.8 percentage points (95% CI = 12.1-13.1). Reductions were observed across maternal demographic groups and in both rural and urban settings, though the extent varied. There was a small reduction in chronic analgesic exposure and a concurrent increase in MOUD. Broad and sustained declines in prenatal prescription opioid exposure occurred over the decade, with little change in the percentage of infants chronically exposed.
Identifiants
pubmed: 38561393
doi: 10.1038/s41372-024-01954-y
pii: 10.1038/s41372-024-01954-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ID : R01HD102125
Organisme : U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ID : R01HD102125
Organisme : U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ID : R01HD102125
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M, Fischer MA, et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiol. 2014;120:1216–24.
doi: 10.1097/ALN.0000000000000172
Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol. 2014;123:997–1002.
doi: 10.1097/AOG.0000000000000208
pubmed: 24785852
pmcid: 4020039
US Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. Morb Mortal Wkly Rep. 2011;60:1487–92.
Maclean JC, Witman A, Durrance CP, Atkins DN, Meinhofer A. Prenatal substance use policies and infant maltreatment reports: study examines prenatal substance use policies and infant maltreatment reports. Health Aff. 2022;41:703–12.
doi: 10.1377/hlthaff.2021.01755
Pac J, Durrance C, Berger L, Ehrenthal DB. The effects of opioid use during pregnancy on infant health and well-being. Ann Am Acad Pol Soc Sci. 2022;703:106–38.
doi: 10.1177/00027162231154338
pubmed: 37799769
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. 2012;307:1934–40.
doi: 10.1001/jama.2012.3951
pubmed: 22546608
Prindle JJ, Hammond I, Putnam-Hornstein E. Prenatal substance exposure diagnosed at birth and infant involvement with child protective services. Child Abus Negl. 2018;76:75–83.
doi: 10.1016/j.chiabu.2017.10.002
Rebbe R, Mienko JA, Brown E, Rowhani-Rahbar A. Hospital variation in child protection reports of substance exposed infants. J Pediatr. 2019;208:141–7.e2.
doi: 10.1016/j.jpeds.2018.12.065
pubmed: 30770194
pmcid: 6486842
Rebbe R, Mienko JA, Brown E, Rowhani-Rahbar A. Child protection reports and removals of infants diagnosed with prenatal substance exposure. Child Abus Negl. 2019;88:28–36.
doi: 10.1016/j.chiabu.2018.11.001
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315:1624–45.
doi: 10.1001/jama.2016.1464
pubmed: 26977696
pmcid: 6390846
Dude C, Jamieson DJ. Assessment of the safety of common medications used during pregnancy. JAMA. 2021;326:2421–2.
doi: 10.1001/jama.2021.20191
pubmed: 34932091
American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119:1070–6.
doi: 10.1097/AOG.0b013e318256496e
Straub L, Huybrechts KF, Hernandez-Diaz S, Zhu Y, Vine S, Desai RJ, et al. Chronic prescription opioid use in pregnancy in the United States. Pharmacoepidemiol Drug Saf. 2021;30:504–13.
doi: 10.1002/pds.5194
pubmed: 33428239
Haegerich TM, Jones CM, Cote PO, Robinson A, Ross L. Evidence for state, community and systems-level prevention strategies to address the opioid crisis. Drug Alcohol Depend. 2019;204:107563.
doi: 10.1016/j.drugalcdep.2019.107563
pubmed: 31585357
pmcid: 9286294
American College of Obstetricians and Gynecologists. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017;130:e81–94.
doi: 10.1097/AOG.0000000000002235
Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5‐year update. J Rural Health. 2019;35:108–12.
doi: 10.1111/jrh.12307
pubmed: 29923637
Wen H, Hockenberry JM, Jeng PJ, Bao Y. Prescription drug monitoring program mandates: impact on opioid prescribing and related hospital use. Health Aff. 2019;38:1550–6.
doi: 10.1377/hlthaff.2019.00103
Austin AE, Bona VD, Cox ME, Proescholdbell S, Fliss MD, Naumann RB. Prenatal use of medication for opioid use disorder and other prescription opioids in cases of neonatal opioid withdrawal syndrome: North Carolina Medicaid, 2016–2018. Am J Public Health. 2021;111:1682–5.
doi: 10.2105/AJPH.2021.306374
pubmed: 34383554
pmcid: 8589053
Nechuta S, Mukhopadhyay S, Golladay M, Rainey J, Krishnaswami S. Trends, patterns, and maternal characteristics of opioid prescribing during pregnancy in a large population-based cohort study. Drug Alcohol Depend. 2022;233:109331.
doi: 10.1016/j.drugalcdep.2022.109331
pubmed: 35149439
pmcid: 10838571
Renny MH, Yin HS, Jent V, Hadland SE, Cerdá M. Temporal trends in opioid prescribing practices in children, adolescents, and younger adults in the US from 2006 to 2018. JAMA Pediatr. 2021;175:1043–52.
doi: 10.1001/jamapediatrics.2021.1832
pubmed: 34180978
Schieber LZ, Guy GP, Seth P, Young R, Mattson CL, Mikosz CA, et al. Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006-2017. JAMA Netw Open. 2019;2:e190665.
doi: 10.1001/jamanetworkopen.2019.0665
pubmed: 30874783
pmcid: 6484643
Hirai AH, Ko JY, Owens PL, Stocks C, Patrick SW. Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010–2017. JAMA. 2021;325:146–55.
doi: 10.1001/jama.2020.24991
pubmed: 33433576
pmcid: 7804920
Wang Y, Berger L, Durrance C, Kirby RS, Kuo D, Pac J, et al. Duration and timing of in utero opioid exposure and incidence of neonatal withdrawal syndrome. Obstet Gynecol. 2023;142:603–11.
doi: 10.1097/AOG.0000000000005289
pubmed: 37548391
Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization—United States, 1999–2014. Morb Mortal Wkly Rep. 2018;67:845.
doi: 10.15585/mmwr.mm6731a1
Brown PR, Thornton K. Technical report on lessons learned in the development of the institute for research on poverty’s Wisconsin administrative data core. 2020. https://www.irp.wisc.edu/wp/wp-content/uploads/2020/08/TechnicalReport_DataCoreLessons2020.pdf
Dietz PM, Bombard JM, Hutchings YL, Gauthier JP, Gambatese MA, Ko JY, et al. Validation of obstetric estimate of gestational age on US birth certificates. Am J Obstet Gynecol. 2014;210:335.e1–e5.
doi: 10.1016/j.ajog.2013.10.875
pubmed: 24184397
Martin JA, Osterman MJ, Kirmeyer SE, Gregory EC. Measuring gestational age in vital statistics data: transitioning to the obstetric estimate. Natl Vital Stat Rep. 2015;64:1–20.
pubmed: 26727629
Basco WT, McCauley JL, Zhang J, Mauldin PD, Simpson KN, Heidari K, et al. Trends in dispensed opioid analgesic prescriptions to children in South Carolina: 2010–2017. Pediatrics. 2021;147:e20200649.
doi: 10.1542/peds.2020-0649
pubmed: 33526605
Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. National, Statistics CfH. Hyattsville, MD; 2014.
Sujan AC, Rickert ME, Quinn PD, Ludema C, Wiggs KK, Larsson H, et al. A population-based study of concurrent prescriptions of opioid analgesic and selective serotonin reuptake inhibitor medications during pregnancy and risk for adverse birth outcomes. Paediatr Perinat Epidemiol. 2021;35:184–93.
doi: 10.1111/ppe.12721
pubmed: 33350491
Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstet Gynecol. 2016;128:4.
doi: 10.1097/AOG.0000000000001446
pubmed: 27275812
pmcid: 4917415
Ko JY, Tong VT, Haight SC, Terplan M, Snead C, Schulkin J. Obstetrician–gynecologists’ practice patterns related to opioid use during pregnancy and postpartum—United States, 2017. J Perinatol. 2020;40:412–21.
doi: 10.1038/s41372-019-0535-2
pubmed: 31616051